NCT05401162 Chemotherapy Supported by Autologous Hematopoietic Stem Cells
| NCT ID | NCT05401162 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chongqing University Cancer Hospital |
| Condition | Ovarian Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2022-04-15 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2022-04-15 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this project is to use autologous haematopoietic stem cell transfusion support to promote the reconstruction of haematopoietic function after chemotherapy for ovarian cancer. To explore the impact of stored haematopoietic stem cell support therapy on bone marrow protection after conventional chemotherapy for ovarian cancer in order to facilitate its clinical application.
Eligibility Criteria
Inclusion Criteria: * 18-60 years old; * there are chemotherapy indicators for ovarian cancer; * ovarian cancer diagnosed by histopathology; * recurrent and metastatic ovarian cancer; * the Eastern Cooperative Oncology Group (ECOG) performance status score≤1; * the expected survival time was more than 3 months; * pre-menopausal women (post-menopausal women must have been postmenopausal for at least 12 months to be considered infertile), and the serum pregnancy test results are negative; * all patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment; * the subjects voluntarily participate in this clinical trial sign an informed consent form and are able to complete the study procedures and follow-up examinations; * bone marrow function is good,ability to perform stem cell mobilisation and collection. Exclusion Criteria: * patients with bone marrow disease; * central nervous system or soft meningeal or bone or bone marrow metastases confirmed by imaging or pathology; * patient has severe cardiac insufficiency; * previous history of allogeneic stem cell transplantation or organ transplantation; * patients with active bleeding and autoimmune thrombocytopenic purpura; * patients with chemotherapy contraindications; * positive for human immunodeficiency virus (HIV); * acute or chronic active hepatitis B or hepatitis C infection.
Contact & Investigator
Dongling Zou, M.D.
PRINCIPAL INVESTIGATOR
Chongqing University Cancer Hospital
Frequently Asked Questions
Who can join the NCT05401162 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 60 Years, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05401162 currently recruiting?
Yes, NCT05401162 is actively recruiting participants. Contact the research team at cqzl_zdl@163.com for enrollment information.
Where is the NCT05401162 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT05401162 clinical trial?
NCT05401162 is sponsored by Chongqing University Cancer Hospital. The principal investigator is Dongling Zou, M.D. at Chongqing University Cancer Hospital. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.